Bladder cancer company Photocure ASA (OSE: PHO) announced on Monday that its partner Asieris Pharmaceuticals (SSE: 688176) presented subgroup data from its Phase III clinical trial for Cevira (APL-1702) at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting.
This trial, focused on the non-surgical treatment of cervical High-Grade Squamous Intraepithelial Lesion (HSIL), demonstrated significant pathological regression and HPV clearance rates, especially in patients aged 20 to 40.
The randomised, double-blind, placebo-controlled trial showed a 15-20% increase in pathological regression in key age groups and strong HPV clearance in younger patients. The drug-device combination offers promise as a non-invasive HSIL treatment, with further validation needed for younger and older age groups.
Cevira achieved its primary efficacy endpoint in 2023, with an NDA accepted by China's NMPA in May 2024.
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial